Merck Pays $830M To End Investor Suit Over Vioxx Marketing

Law360, New York (January 15, 2016, 11:13 AM EST) -- Merck announced Friday that it will pay $830 million to settle investors' claims in multidistrict litigation accusing the company of committing securities fraud violations by illegally marketing the painkiller Vioxx, after the drugmaker previously agreed to pay a criminal penalty of nearly $1 billion in 2011.

(Credit: AP) In a statement, Merck & Co. Inc. denied any wrongdoing, and noted that it still faces individual lawsuits stemming from the same alleged misconduct — namely, that it marketed the anti-inflammatory drug for off-label uses and downplayed its risk of causing heart attacks.

"After available funds under certain insurance policies, Merck's cash payment...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!